Skip to main content

Remote Job Finders (RJF)

Caught In Sarepta ‘Downdraft,’ Arrowhead Becomes RNAi Knight in Shining Armor

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline this past month. BioSpace caught up with Arrowhead’s Chris Anzalone to talk about the biotech’s role as an RNAi pipeline savior.

Gilead Confident in PrEP Franchise Even Amid Preventive Task Force Uncertainties

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV PrEP Yeztugo—that insurers must cover. A recently postponed meeting has raised concerns that Health Secretary RFK Jr. could abolish or overhaul the group.

Lilly Faces Triple Threat of Drug Pricing Pressure as CEO Emphasizes Value

From the price of forthcoming weight loss pill orforglipron, to Most Favored Nation drug pricing and the market battle with Novo Nordisk, pricing was the number one issue for Eli Lilly on its second quarter earnings call.

Hiring Outlook: Latest Job, Application Numbers Highlight Tough Job Market

Higher competition for fewer roles remains the status quo for biopharma professionals, based on BioSpace data. Additionally, the U.S. Bureau of Labor Statistics has reported that recent job growth is lower than previously believed.
Scroll to top